Sanofi-Aventis Merger Set; $65 Bil. Deal Means More Leverage With Managed Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' $30 bil. pharma/vaccine business will provide bulk necessary to better negotiate discounts. Sanofi has not had much opportunity to work within U.S. managed care system, but says it will learn from Aventis.
You may also be interested in...
Sanofi-Aventis Nominates Le Fur For CEO Post In 2007
Under the proposal, Sanofi-Aventis CEO Dehecq will remain as chairman for three years to ensure a smooth transition.
Sanofi-Aventis Nominates Le Fur For CEO Post In 2007
Under the proposal, Sanofi-Aventis CEO Dehecq will remain as chairman for three years to ensure a smooth transition.
Sanofi May Increase Sales Force Despite Need To Meet Post-Merger Savings Goal
The company says it is on target to achieve its previously announced $2.1 bil. in synergies and is not planning to cut its R&D and promotional budgets to achieve that number. Sanofi-Aventis says Acomplia pre-launch expenses will run into the hundreds of millions of euros.